QDEL - Quidel more quick diagnosis Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : QDEL - Quidel more quick diagnosis

QDEL 21.27

+0.9%

Nov 18 3:59 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Ted Gregg who wrote (936)	7/4/1997 7:11:00 AM
From: Mike Relyea	of 1693

Here's an article in the Wall Street Journal Interactive Edition than mentions Abbott's antibiotic Biaxin has been enjoying strong sales. A good indication that the testing and treatment market for H. pylori's increasing: Abbott Laboratories Dow Jones Newswires -- July 3, 1997 interactive3.wsj.com@1.cgi?id=BT-CO-19970703-002440.djml&template=pj1-combo-nf.tmpl Medical Device Cos. Expected To Report Strong 2Q Earnings By LOUIS HAU Dow Jones Newswires Abbott Laboratories (ABT) should post earnings of 69 cents a share, compared with 60 cents in the year-ago period, Salomon's Kammerman said. The North Chicago, Ill., company should see an improvement in its operating margin as its product mix shifts to more profitable products, he said. The company's antibiotic Biaxin has been enjoying strong sales, spurred most recently by the Food and Drug Administration's approval of the use of the drug to cure peptic ulcers, he said. . . . . Mike

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next